Advancing targeted, controllable, multigenic therapies for cardiovascular diseases


Triple-Gene is a gene therapy company focused on developing advanced therapies for complex cardiovascular diseases.

The Challenge

  • 25 million patients globally suffer from heart failure
  • ~6.5M patients in the US affected
  • About every 90 seconds a person in the US dies from heart disease

Developing a holistic treatment for heart failure requires improvements in angiogenesis, calcium homeostasis-associated cellular energetics, reductions in inflammatory signals, and the activation/recruitment of stem cells to support heart remodeling. We are focused on advancing targeted, controllable, and multigenic gene therapies for the treatment of cardiovascular diseases.

Triple-Gene is a majority-owned subsidiary of Precigen.

Heart failure is a complex clinical syndrome. Frequently initiated by injury to the heart, only rarely is heart failure caused by a single genetic lesion. Precigen Triple-Gene’s unique therapeutic approach combines a multigenic therapy with delivery directly to cardiac tissue to address underlying disease mechanisms. We believe targeting multiple points in the disease progression pathway is necessary to effectively treat heart failure pathologies and bring relief to patients suffering from this devastating disease.

Our Approach

Our unique approach implements technologies that are targeted, controllable and multigenic.

  • Targeted: We employ genome delivery systems designed to match disease and/or injury-related specifications.
  • Controllable: We create modulated gene systems in concert with DNA/RNA/protein-based regulatory motifs, to enable spatiotemporal controls over one or more therapeutic effector molecules.
  • Multigenic: We optimize multi-effector therapies to advance treatment or cure underlying disease etiologies and also to ameliorate effects of chronic comorbid tissue damage.

Our Platform Advantages

Triple-Gene’s multigenic therapies are designed to drive expression of three or more potent gene products targeted at reprogramming cells and organs toward a positive health state. Our genetic architecture is built upon a suite of integrated platform technologies. We employ non-viral delivery of DNA to develop therapeutics that address the underlying causes of cardiovascular disease.

  • Non-viral delivery eliminates issues of immunogenicity seen with viral-based methods
  • Multigenic therapies can target multiple aspects of disease
  • Our approach has enabled proof-of-concept to clinical IND in under 24 months.

Administration of our plasmid DNA therapy through the RCSI approach allows for delivery via capillary filtration increased by hydrostatic and osmotic pressures. The efficiency of transduction is dependent on the volume and time of infusion.

Triple-Gene Careers

Interested in joining our team?

Learn More


Contact Us